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Background: Pseudomonas aeruginosa is an opportunistic pathogen mostly affecting hospitalized and immunodeficient patients. Considering the extent of attention paid to the issue of antibiotic resistance and the origin of such resistance and the growing number of treatment failures in patients with burn injury, it seems that investigating the degree of ampC gene expression could be beneficial for the treatment of patients with severe burn injury.
Objectives: The present study focused on identifying different antibiotic patterns, detecting carbapenem resistant Pseudomonas aeruginosa strains isolated from severely burned patients and investigating AmpC gene expression as one of the important mechanisms associated with drug resistance.
Materials and Methods: A total of 189 clinical isolates of carbapenem resistant Pseudomonas aeruginosa, isolated from patients with severe burn injuries, were identified by bacteriological methods followed by determination of their antibiotic resistance patterns by the standard protocol of Kirby–Bauer. The expression of ampC gene was determined by quantitative real-time PCR.
Results: Based on our findings, 94.2% of the isolates were resistant to imipenem, 99.5% were resistant to meropenem, and all were resistant to ertapenem. The level of ampC gene expression in carbapenem resistant Pseudomonas aeruginosa isolates, compared to standard carbapenem sensitive strains, was significantly increased.
Conclusions: Our data showed that the over-expression of ampC gene is an important mechanism of resistance in carbapenem resistant Pseudomonas aeruginosa strains isolated from severely burned patients with secondary infections.
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1. BackgroundPseudomonas aeruginosa is an opportunistic, aerobic gram-negative pathogen that possesses lipopolysaccha-rides, a single polar flagellum and pili. Flagellum, the motility organ of bacteria, confers bacteria the ability to change direction and is important for attachment of bac-teria to cell membranes thus, plays a vital role, as a viru-lence factor, in hospitalized immunodeficient patients (1). The ability of bacteria in developing β-lactamases leads to the emergence of the resistance phenomenon in many species of microorganisms, in particular those re-sponsible for nosocomial infections, making treatment strategies for such infections extremely complicated (2). The spectrum of β-lactamase activity of some bacte-ria may expand, leading to the appearance of extended spectrum β-lactamase (ESBL)-producing organisms. Bac-terial β-lactamases are divided into four major groups (A-D) according to the Ambler classification scheme. 
Group A hydrolyze penicillin and cephalosporins; group B are metallo-β-lactamases (MBLs) requiring Zn2+ ion(s) for activity; group C include enzymes such as AmpC-type β-lactamases (3) that degrade cephamycins and cephalo-sporins; and group D are β-lactamases with high hydro-lysis rate. AmpC-induced resistance is of serious concern in Pseudomonas aeruginosa (4). Resistance to carbapen-ems in Pseudomonas aeruginosa may be due to the pro-duction of AmpC-type β-lactamases (5). Also, AmpC-type β-lactamases cause bacteria to become resistant to aztreo-nam and inhibit class A enzymes such as clavulanic acid. The most relevant mechanism for expanding resistance to antipseudomonal penicillins and cephalosporins is the occurrence of mutations that produce chromosom-ally mediated AmpC β-lactamases with the potential to hydrolyze cephalosporins. These mutations occur during the course of antibacterial therapy, leading to treatment 
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failure (6). Despite numerous advances in treating patients with severe burn injuries, these injuries are still one of the most important causes of mortality throughout the world with burn wound infections and secondary sepsis as the most important complication following major burn inju-ries (7). Most deaths (75%) in patients with severe burns of greater than 40% of the total body surface are currently as-sociated with blood infections and burn wound infections or other infection complications and respiratory damages. Also, burn injury damages the first line of the host defense barriers and suppresses the body defense system, facilitat-ing the entry of opportunistic and pathogenic organisms such as Pseudomonas aeruginosa and Staphylococcus aureus into the body. Upon injury, the initial colonization occurs with gram-pos-itive and gram-negative bacteria from the patient's endog-enous skin flora and later by microorganisms transmitted from the hospital environment (8). Vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus au-reus (MRSA), and multidrug-resistant gram-negative bac-teria (MDRGN) which contain several types of β-lactamases including extended spectrum β-lactamases (ESBLs), AmpC β-lactamases and metallo-β-lactamases are among the most important pathogenic bacteria affecting hospitalized pa-tients (9).Considering the intrinsic and acquired properties of Pseudomonas aeruginosa, compared to enterobacteria-ceae, these organisms are resistant to many antibacterial agents. Antibacterial treatment against these organisms is performed by administrating synthetic penicillins, third-generation cephalosporins, carbapenems, monobactams, aminoglycosides, fluoroquinolones and polymyxins; com-monly a combination of an aminoglycoside plus a β-lactam drug, third-generation cephalosporin, monobactams or carbapenem is preferred. However, combination therapy is a matter of controversy and has been emphasized that mono-therapy could be as effective as combined therapy if an appropriate antibacterial agent is administered at the correct dose and the right time (10). Carbapenems are the drug of choice when fighting ESBLs-producing Pseudo-monas aeruginosa because of their high-level of stability against the hydrolytic activity of ESBLs, small size, and their double-ring structure which eases their passage through the bacterial outer membrane (11). However, the rate of treatment failure and mortality following the administra-tion of carbapenems is still high while, the development of resistance during therapy against Pseudomonas aeru-ginosa infections occurs in many cases, depending on the drug dosage, type of drug used, and the location of infec-tion. Among carbapenems, there is greater possibility for developing resistance against imipenem during the course of treatment (12). The emergence of resistance against imi-penem in Pseudomonas aeruginosa seems to be in coordi-nation with the loss of oprD and AmpC β-lactamase activ-ity (13). Clinicians recommend that the initial treatment should be started with a combination of an antipseudo-monal β-lactam drug plus an aminoglycoside (12).
2. ObjectivesThe present study focused on identifying different an-tibiotic patterns, detecting carbapenem resistant Pseudo-monas aeruginosa strains isolated from severely burned patients, and investigating AmpC gene expression as one of the important mechanisms associated with drug resis-tance.
3. Materials and MethodsA total 189 clinical isolates of carbapenem-resistant P. aeruginosa were collected from different burn units in Tehran (Iran) during 2011 and 2012. Clinical isolates were confirmed by standard bacteriological methods per-formed at the medical microbiology laboratory of Qazvin University of Medical Sciences. Briefly, the organisms in-cluded in the study were gram-negative obligate aerobic bacteria with a positive oxidase test, inability to ferment glucose or lactose under anaerobic conditions in oxida-tion/fermentation medium (OF), and ability to grow on different culture media such as blood agar, MacConkey agar, eosin methylene blue agar, and cetrimide agar. The antibiotic-resistance profile of isolated organisms was evaluated by the Kirby Bauer disk diffusion assay accord-ing to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The antibiotics used were imipenem (10 µg), meropenem (10 µg), ertapenem (10 µg); all obtained from the MAST Company (England). A standard strain of P. aeruginosa (ATCC 27853) was used as the control organ-ism. To investigate the level of ampC β-lactamase gene expression, a quantitative real-time polymerase chain reaction (qRT-PCR) assay was employed. For RNA extrac-tion and performance of RT-PCR, P. aeruginosa isolates were cultured in 1.5 mL lysogeny broth (LB) and left in a shaking incubator (180 rpm) at 37 оC for 18-24 hours. Later, following overnight incubation, the cultures were centrifuged (8000 rpm) at 4 оC for seven minutes. The sediment obtained was used for extraction of total RNA using a commercial kit (RNeasy kit, Qiagen, Germany), ac-cording to the manufacturer's instructions. The elimina-tion of genomic DNA was achieved using a commercial RNase-free DNase kit (DNase |, RNase-free, Fermentas, Thermo Scientific, USA) according to the manufacturer's instructions. To prepare cDNA, 5 µL of extracted RNA was added to 15 µL distilled, deionized water and converted to cDNA in a total volume of 20 µL using a commercial kit (cDNA kit, BioNeer Pacific, Australia) according to the manufacturer's instructions. The quality and quantity of extracted RNA was assessed by electrophoresis on aga-rose gel. Real-time PCR was performed using the Applied Biosystems 7500 real-time PCR (Fort Collins, Colorado, USA) and a commercial kit (SYBR® Green2X Master Mix; Applied Biosystems, USA). Briefly, using a standard 96-well microplate (Applied Biosystems; USA), a volume of 0.5 µL of each primer, 5 µL cDNA, 4 µL distilled deionized water, and 10 µL of Master Mix were added to each well. All PCR reactions were performed in a 20 µL volume for 
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45 cycles. After PCR performance, a melting curve was drawn to evaluate the specificity of the PCR reaction (Fig-ures 1 and 2) followed by electrophoresis of PCR products on 2% agarose gel (Figure 3). Specific primers of ampC (Table 1) were used to evaluate changes of ampC gene ex-pression in carbapenem-resistant P. aeruginosa isolates. Housekeeping gene rpoD was used as an internal stan-dard for normalizing the level of transcription of target genes and the standard P. aeruginosa strain (ATCC 27853) for comparative evaluation of the gene mentioned above.
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Figure 1. ampC Gene Linear Amplification Plot
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Figure 2. Melting Curve Plot for the Isolates With ampC gene
Figure 3. PCR Product
Line1: 100 bp DNA molecular marker; lines 2-5 and 7-11: positive samples; line 6: negative control
Table 1.  Primers Used to Evaluate the ampC β-lactamase Gene Expression
Gene Primer Sequence
AmpC For 5´-CGCCGTACAACCGGTGAT-3´Rev 5´-CGGCCGTCCTCTTTCGA-3´
rpoD For 5´-GGGCTGTCTCGAATACGTTGA-3´Rev 5´-ACCTGCCGGAGGATATTTCC-3´
3.1. Method Used to Evaluate Gene ExpressionOnce the PCR reaction was over, the threshold line was determined and the data were analyzed by descriptive statistics using the Microsoft Excel software. To deter-mine the output and correlation coefficient of the target gene (ampC) and the housekeeping gene (rpoD) from extracted RNA, serial dilutions were prepared and follow-ing performance of RT-PCR, a standard curve was drawn for each segment of the gene. Later, the CT of samples was used to calculate the increase or decrease in gene expres-sion using the 2-ΔΔCT method. 
4. ResultsThe findings of the drug susceptibility assay using the Kirby-Bauer disk diffusion technique on 189 carbapen-em-resistant P. aeruginosa, isolated from burn wounds, revealed 94.2%, 99.5%, and 100% resistance rate towards imipenem, meropenem and ertapenem, respectively. The results of this study indicate that the ampC gene expres-sion was increased in all studied isolates compared to the rpoD housekeeping gene. Of the 189 clinical isolates of Pseudomonas aeruginosa, 94.2%, 99.5%, and 100% were resistant to imipenem, meropenem and ertapenem, re-spectively.
5. DiscussionBeta-lactam drugs compose more than 50% of all anti-biotics used in clinics (14) yet the therapeutic benefits of this group of drugs is decreasing because of the grow-
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ing prevalence of bacterial resistance mechanisms (15). The eminent resistance mechanism against the β-lactam drugs in Pseudomonas aeruginosa and many other non-fermenting gram-negative bacteria, like many members of the family Enterobacteriaceae, is the production of AmpC β-lactamases (16, 17). The AmpC β-lactamases are responsible for inactivating a broad spectrum of diverse β-lactam drugs such as penicillins, cephalosporins and monobactams (18). The most relevant mechanism for expanding the resistance phenomenon to antipseudo-monal penicillins is the occurrence of mutations that lead to hyperproduction of the chromosomal cephalo-sporinase AmpC. During the course of treatment with β-lactam agents, resistant mutations with constitutive AmpC over-production are commonly selected, resulting in treatment failure (6). The development of resistance against imipenem in Pseudomonas aeruginosa seems to be the interplay between AmpC β-lactamase overpro-duction and the loss of OprD (13). In the current study, the CT values obtained for ampC and rpoD genes in car-bapenem-sensitive Pseudomonas aeruginosa isolates were 31.6422 ± 3.8728 and 32.011 ± 6.1982, respectively, with ΔCT of 0.3688. Likewise, the CT values calculated for ampC and rpoD genes in carbapenem-resistant Pseudomonas aerugi-nosa strains isolated from patients were 33.9869 ± 3.8728 and 24.3809 ± 5.5262, respectively, with a value of -9.9768 for ΔCT. Considering the formula 2-ΔΔCT, it is clear that the level of ampC gene expression in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa was 1300 times greater than that found for carbapenem-sensitive Pseudomonas aeruginosa used as the standard strain. Quale et al. in 2006 studied 33 isolates of Pseudomonas aeruginosa with different susceptibility patterns against carbapenem and tested these organisms for the expres-sion of ampC, oprD, and efflux genes using RT-PCR. Based on the RT-PCR findings, these clinical strains were divid-ed into three groups among those, 13 isolates from group one showed AmpC overproduction (19). Also, Cabot et al. in 2011 evaluated the prevalence and effect of AmpC and efflux pump overexpression in 190 clinical strains of Pseu-domonas aeruginosa isolated from blood samples using real-time PCR and showed AmpC overproduction in 24.2% of isolates (20). In another study by Xavier et al. in 2010, the level of expression for efflux pump, oprD, and ampC genes in Pseudomonas aeruginosa strains was evaluated in which 52.5% of isolates were resistant to carbapenems while 11.9% showed no Ampc overproduction (21). Finally, Tomas et al. in 2010 examined 25 clinical strains of Pseu-domonas aeruginosa, isolated from patients with cystic fibrosis, for the expression of ampC, oprD, mexA, mexC, mexE, and mexX genes and demonstrated an overexpres-sion for the mexA and ampC genes yet a reduced level of expression for the oprD gene, a finding correlated with resistance against β-lactams (22). Considering the extent of attention paid to the issue of antibiotic resistance and the origin of such resistance and as there is a growing number of treatment failures in pa-
tients with burn injury, it seems that investigating the de-gree of ampC gene expression could be beneficial for the treatment of patients with severe burn injury. The present study focused on identifying different antibiotic patterns, detecting carbapenem resistant Pseudomonas aeruginosa strains isolated from severely burned patients, and inves-tigating the AmpC gene expression as one of the impor-tant mechanisms associated with drug resistance. This is the first report from Iran concerning one of the resistance mechanisms against carbapenem, i.e. AmpC β-lactamase expression in Pseudomonas aeruginosa. On a nationwide scale, the findings of this study are of crucial importance and could be implemented in broadening a new strategy for antipseudomonal treatment. Changes in the strategy of antibiotic administration and establishing appropriate infection control measures in hospital wards, in particular those designed for long-term hospitalization such as burn units, are important factors that could, to some extent, prevent the dissemina-tion of carbapenem-resistant organisms.
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